JAB-3068

SHP2 inhibitor · Jacobio Pharmaceuticals Co., Ltd.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for JAB-3068, covering 2024-09-19 to 2024-12-16. Get the full timeline:

Most recent: Clinical Trial Update: A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors [Phase 1]

See pricing